Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

IMPORTANCE: Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been repor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA Oncol
Auteurs principaux: Reardon, David A., Brandes, Alba A., Omuro, Antonio, Mulholland, Paul, Lim, Michael, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet S., Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan Manuel, De Souza, Paul, Sahebjam, Solmaz, Carleton, Michael, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Sampson, John, Weller, Michael
Format: Artigo
Langue:Inglês
Publié: American Medical Association 2020
Sujets:
Original Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7243167/
https://ncbi.nlm.nih.gov/pubmed/32437507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.1024
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires